desvenlafaxine succinate (DVS) SR + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Jun 1, 2008 → May 1, 2010

NCT ID

NCT00683800

About desvenlafaxine succinate (DVS) SR + Placebo

desvenlafaxine succinate (DVS) SR + Placebo is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00683800. Target conditions include Vasomotor Symptoms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00683800	Phase 3	Completed	Jun 1, 2008	May 1, 2010	Vasomotor Symptoms

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors

Product	Company	Stage	Hype Score
fezolinetant + placebo	Astellas Pharma	Phase 3	77
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol	Eli Lilly	Phase 2	52
esomeprazole + placebo	AstraZeneca	Pre-clinical	23
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg	Merck	Phase 2	52
Erenumab + Placebo	Amgen	Phase 1	32
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)	Pfizer	Approved	84
DVS-233 SR	Pfizer	Phase 3	76
Bazedoxifene/Conjugated Estrogen	Pfizer	Phase 3	76
desvenlafaxine succinate sustained release (DVS SR)	Pfizer	Phase 1	32
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release	Pfizer	Phase 3	76
Treatment A + Treatment B + Treatment C	Bayer	Phase 1	30
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	30
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 3	74
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment B	Bayer	Phase 1	30
Elinzanetant (BAY3427080)	Bayer	Phase 1	30
Moxifloxacin + Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	30
Elinzanetant (BAY3427080) + Dabigatran etexilate	Bayer	Phase 1	30
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg	Bayer	Phase 3	74
BAY3427080	Bayer	Phase 1	30
Elinzanetant (BAY3427080) + Rosuvastatin	Bayer	Phase 1	30

Other Products from Pfizer